Pharma's Big Win: How a Judge's Ruling Ignited Big Pharma Stocks

Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Apellis Pharmaceuticals Faces Investor Jitters as Goldman Sachs Issues "Sell" Rating on Escalating Competitive Threats

Amneal Pharmaceuticals Eyes Major Market Entry with Xolair Biosimilar, Pledging Affordable Relief

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Novartis Plots Strategic Price Adjustments in US as Trump's MFN Deadline Looms

Roche's Strategic Investment Ignites Excitement in the MASH Drug Development Landscape

Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave

Unlocking Monopar's Potential: A Speculative Bet on Imminent Cancer Breakthroughs

Amgen may be evaluating Cytokinetics bid; CYTK wants $130 $145 a share report

Cytokinetics plunges amid no deal announcement as JPMorgan conf set to end